Cardiome Announces Commercialization Partnership For BRINAVESS™ In Select European Markets

  Cardiome Announces Commercialization Partnership For BRINAVESS™ In Select
                               European Markets

PR Newswire

VANCOUVER, July 3, 2013


VANCOUVER, July 3, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced an agreement with AOP Orphan Pharmaceuticals AG,
headquartered in Vienna, Austria, to commercialize BRINAVESS™ (vernakalant
intravenous) in select European markets. AOP Orphan will support Cardiome in
obtaining product registrations required for the marketing and sale of
BRINAVESS in the AOP Orphan countries and will actively call on customers to
promote the product. Under terms of the agreement, AOP Orphan has agreed to
specific annual commercial goals for BRINAVESS. Financial details of the
agreement were not disclosed.

"Execution of the BRINAVESS  commercial agreement with  AOP Orphan fulfills  a 
key objective in Cardiome's European commercialization strategy," said William
Hunter, M.D., CEO of Cardiome.  "Through the agreement, additional  physicians 
and patients beyond the reach of our  current sales force will have access  to 
BRINAVESS. We  are very  pleased to  have partnered  with such  a  well-known, 
highly experienced and respected company."

"We are excited to partner and work with Cardiome, and to add BRINAVESS to our
cardiovascular drug  portfolio,"  said Rudolf  Widmann,  Ph. D.,  CEO  of  AOP 
Orphan. "The synergies  that exist  between BRINAVESS  and our  cardiovascular 
franchise should enable us to build on our existing customer base by  offering 
a complementary product and develop  new customer relationships which are  key 
to our future growth."

The initial term  of this  commercial agreement begins  July 1,  2013 for  the 
duration of  three years  and is  renewable  on an  annual basis,  or  longer, 
thereafter. The AOP Orphan countries include: Austria; Bosnia and Herzegovina;
Bulgaria; Croatia;  Czech  Republic;  Estonia;  Hungary;  Kazakhstan;  Latvia; 
Lithuania; Montenegro; Macedonia; Poland; Romania; Serbia; Slovakia; Slovenia;
Switzerland; and Ukraine.

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one marketed
product, BRINAVESS™ (vernakalant IV), approved in Europe and other territories
for the rapid conversion of recent onset atrial fibrillation to sinus rhythm
in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock
Exchange (COM). For more information, please visit our web site at

Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions.
Forward- looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations, research and
development and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions in the United States, Canada, Europe, and the
other regions in which we operate; market demand; technological changes that
could impact our existing products or our ability to develop and commercialize
future products; competition; existing governmental legislation and
regulations and changes in, or the failure to comply with, governmental
legislation and regulations; availability of financial reimbursement coverage
from governmental and third-party payers for products and related treatments;
adverse results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety and/or efficacy
of our products or products; decisions, and the timing of decisions, made by
health regulatory agencies regarding approval of our technology and products;
the requirement for substantial funding to expand commercialization
activities; and any other factors that may affect our performance. In
addition, our business is subject to certain operating risks that may cause
any results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our
ability to successfully complete pre-clinical and clinical development of our
products; changes in our business strategy or development plans; intellectual
property matters, including the unenforceability or loss of patent protection
resulting from third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture, market and
sell our products; the availability of capital to finance our activities; and
any other factors described in detail in our filings with the Securities and
Exchange Commission available at and the Canadian securities
regulatory authorities at Given these risks, uncertainties and
factors, you are cautioned not to place undue reliance on such forward-looking
statements and information, which are qualified in their entirety by this
cautionary statement. All forward-looking statements and information made
herein are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to reflect
subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.


Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928
Press spacebar to pause and continue. Press esc to stop.